Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals
- PMID: 8794311
- PMCID: PMC190717
- DOI: 10.1128/JVI.70.10.6741-6750.1996
Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals
Abstract
Cytotoxic T lymphocytes (CTL) may be important to prevent cell-to-cell transmission of human immunodeficiency virus type 1 (HIV-1), the agent responsible for AIDS. In this study, we investigated the epitope specificity of CTLs induced in individuals immunized against the virus envelope glycoprotein gp160. The determinant of HIV-1 gp160 for the stimulation of CTL is located in a region of high sequence variability among HIV-1 isolates, the so-called V3 loop P18. Using a panel of P18 peptides, we compared the CTL specificities of cells from two individuals immunized with vaccinia virus recombinants expressing the envelope glycoproteins from two different strains of HIV-1, IIIB and SIMI. For this purpose, CTLs specific for the IIIB P18 peptide (RIQRGPGRAFVTIGK) were compared with CTLs for the site from the SIMI isolate (TLHMGPKRAFYATGD). The results indicate that in contrast to CD8+ CTLs induced by the glycoprotein from strain IIIB, CD8+ CTLs induced by strain SIMI strongly cross-reacted with targets presenting P18 peptides as well as envelope proteins from the divergent MN and RF isolates but failed to cross-react with targets that presented the IIIB peptide. These data have implications for the design of an HIV vaccine.
Similar articles
-
Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.J Virol. 1998 Oct;72(10):8264-72. doi: 10.1128/JVI.72.10.8264-8272.1998. J Virol. 1998. PMID: 9733870 Free PMC article.
-
Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates.J Virol. 2002 May;76(9):4222-32. doi: 10.1128/jvi.76.9.4222-4232.2002. J Virol. 2002. PMID: 11932387 Free PMC article.
-
Lymphoproliferative response to synthetic V3 loop P18 peptide and HIV-1 envelope glycoprotein among individuals immunized with gp160 candidate vaccines.Biomed Pharmacother. 1996;50(10):494-9. doi: 10.1016/s0753-3322(97)89280-3. Biomed Pharmacother. 1996. PMID: 9091063
-
HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.Virus Genes. 1994 Jul;8(3):249-70. doi: 10.1007/BF01704519. Virus Genes. 1994. PMID: 7975271 Review.
-
"HIV-peplotion vaccine"--a novel approach to protection against AIDS by transepithelial transport of viral peptides to Langerhans cells for long-term antiviral CTL response. (A review).Acta Microbiol Immunol Hung. 1996;43(1):1-17. Acta Microbiol Immunol Hung. 1996. PMID: 8806938 Review.
Cited by
-
Induction of human immunodeficiency virus (HIV-1) envelope specific cell-mediated immunity by a non-homologous synthetic peptide.PLoS One. 2007 Nov 28;2(11):e1214. doi: 10.1371/journal.pone.0001214. PLoS One. 2007. PMID: 18043730 Free PMC article.
-
Restoration of immune response by a cationic amphiphilic drug (AY 9944) in vitro: a new approach To chemotherapy against human immunodeficiency virus type 1.Antimicrob Agents Chemother. 1998 Oct;42(10):2482-91. doi: 10.1128/AAC.42.10.2482. Antimicrob Agents Chemother. 1998. PMID: 9756745 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials